Mazdutide Developed by Innovent Biologics in partnership with Eli Lilly, mazdutide is another GLP-1/glucagon dual agonist currently in advanced clinical trials, primarily in China
In these trials, MOUNJARO (5 mg, 10 mg, and 15 mg given subcutaneously once weekly) was compared with placebo, semaglutide 1 mg, insulin degludec, and/or insulin glargine [see Clinical Studies (14.2, 14.3, 14.4)]
Retrieved 26 September 2020
Tirzepatide is given as a once weekly subcutaneous injection, typically in the abdomen, thigh, or upper arm
doi: 10.1056/NEJMoa2404881 34
If you're travelling to hot climates, use a cooling case to keep it at the right temperature